Christine said: "Tests conducted by the Animal and Plant Health Agency have confirmed that the virus responsible for COVID-19 has been detected in a pet cat in England.
"This is a very rare event with infected animals detected to date only showing mild clinical signs and recovering within in a few days.
"There is no evidence to suggest that pets directly transmit the virus to humans. We will continue to monitor this situation closely and will update our guidance to pet owners should the situation change."
Yvonne Doyle, Medical Director at Public Health England, said: "This is the first case of a domestic cat testing positive for COVID-19 in the UK but should not be a cause for alarm.
"The investigation into this case suggest that the infection was spread from humans to animal, and not the other way round. At this time, there is no evidence that pets can transmit the disease to humans.
The pet cat was initially diagnosed by a vet with feline herpes virus, but the sample was also tested for SARS-CoV-2 as part of a research programme at the Centre for Virus Research at Glasgow University. Follow-up samples tested at the APHA laboratory in Weybridge confirmed the cat was also co-infected with SARS-CoV2 , the virus known to cause COVID-19 in humans.
BSAVA advice for practising vets about coronavirus is here and further information about testing is available here.
The main changes announced today are:
In the future, the revalidation interval, which currently ranges from two to five years depending on the course, will be standardised at 4 years.
Currently, there is a two-month window in which Official Veterinarians (OV) can submit their final declarations, on completion of the course, if they want to set their next revalidation interval from the end of the window.
The revalidation window will be extended to a six-month period prior to the completion deadline date. If completed in this window, the date of the next revalidation would be taken from the deadline date and not the date of completion.
APHA is discussing ways of making invigilation more flexible, to help those working in sole-charge or remote practices. One option being investigated with course accreditation providers is remote invigilation, though this would come at extra cost.
All the multiple choice questions in the online exams are being reviewed to make sure they test the ability to perform the role, and in the future, candidates will be given more feedback at the end of the test (ie which questions they answered incorrectly).
In terms of CPD requirements, there will be clarification on what can be considered relevant CPD towards the 10 hours that need to be completed over the four-year timeframe.
Lastly, APHA has announced a raft of changes concerning course content, and that it will itself review all the courses to consider how the number of courses and topics can be rationalised, how to reduce the number of qualifications any OV might need and/or the time spent revalidating, and how to reduce the content without losing quality.
The BVA, which spearheaded the campaign for reform, has welcomed the announcement. Simon Doherty, BVA President, said: "We’re delighted that APHA has taken on board our members’ concerns with the current system and proposed improvements that should make the process much more fair and consistent while continuing to maintain high standards. This is a really crucial time for ensuring that the workforce retains skilled professionals and is at full strength to keep animal welfare standards high, protect public health and meet demand for export certification after Brexit.
"This piece of work is a shining example of what can be achieved when vets pull together to air concerns and make the case for change. We will continue to work closely with APHA to explore and put in place ways of making the revalidation process as fit for purpose as possible for this critical section of the workforce."
Full review: http://apha.defra.gov.uk/documents/ov/Briefing-Note-0519.pdf
Whilst you're here, take a moment to see our latest job opportunities for vets.
Dr Berwyn Clarke, CEO of PBD Biotech, which developed the bacteriophage-based detection method, says this is significant step forward: "In situations where a farm has had an ongoing chronic bovine TB problem, APHA’s protocol offers a promising new approach to controlling the infection.
"Actiphage is now included within a series of measures that farmers can use in conjunction with their vet and with specific APHA approval as a means to improving their disease management strategy.
"For many farms that have been struggling for years it provides the first step to becoming TB free. This move by the APHA is a really positive step towards tackling this devastating disease."
Much of this new strategy, as part of a private TB eradication plan, has been driven by the success of Devon-based vet Dick Sibley, who incorporated Actiphage into a disease management strategy last Autumn to help clear a dairy herd that had been stricken with TB since 2012.
Dick said: "The approach of directly measuring the presence of live bacteria in the blood in just six hours is a totally different but complementary measurement to other technologies and has enabled enhanced testing, early detection and containment of the infected animals.
"We don’t have all of the answers yet, but it’s about predicting, preventing and managing what we can – and Actiphage has contributed greatly to the outcome we’ve been after for so long."
The Exceptional private use of non-validated tests for TB on cattle in England protocol enables any private veterinary surgeon to request APHA permission for exceptional use of Actiphage and the other non-validated tests, subject to certain criteria that include herd supplementary interferon-γ (IFN- γ) testing, discussions with the APHA Case Vet and the farmer’s written consent.
Berwyn added: "Actiphage is unique in directly detecting live mycobacteria in blood or milk, and it can also distinguish between a vaccinated and an infected animal - paving the way for new types of disease control when vaccines become available in the future.
"We are working with international governments, and the test is being trialled on bovine, ovine as well as exotic species, but we appreciate it is new to the UK market so we’re keen to answer any queries vets or farmers may have."
The new test will be profiled in the Innovation Hub at the Royal Norfolk Agricultural Show next month (27 & 28 June).
PBD Biotech says Actiphage will require further testing before it is officially approved for standard veterinary use in the UK, however under the APHA protocol it is now permitted for private use where herds have experienced persistent breakdowns and this will contribute to the evidence-base required for official validation by the OIE and acceptance by APHA.
Within this protocol, APHA has outlined a number of other non-validated tests that may be proposed for exceptional use in cattle herds with chronic breakdowns, including: the Actiphage assay, developed by PBD Biotech and Nottingham University; the Enferplex TB serological test, produced by Enfer Laboratories Ireland and approved in GB for use in camelids; and the Polymerase Chain Reaction (PCR) testing of faecal samples. APHA says this is not an exhaustive list and that the protocol covers any current or future non-validated tests for bovine TB.
The comparative intradermal tuberculin skin test and the IFN- γ blood test remain the only ante mortem tests currently approved for the statutory cattle TB testing programme in Great Britain.
The full Exceptional private use of non-validated tests for TB on cattle in England is available on the APHA Vet Gateway: apha.defra.gov.uk/vet-gateway/non-valid-tb-testing